The Jackson Laboratory

11/06/2025

JAX has long been recognized as a global leader in biomedical research for its pioneering work in genetics, genomics and the development of mouse models that have transformed our understanding of human disease. But JAX’s expertise doesn’t stop at the organismal level. JAX researchers are also at the forefront of advances in stem cells and cell modeling. 🧬

From stem cells that can become almost any cell type in the body, to AI-powered systems that analyze complex data, JAX researchers are accelerating the path from discovery to treatment — and shaping the future of precision medicine.

How JAX scientists are using stem cells to build better models, faster insights and smarter treatments.

11/05/2025

Genomics is already transforming how doctors diagnose and treat patients, yet many health care providers graduate without formal genetics training. The Jackson Laboratory's Clinical Education team and the University of New England are working to change that.

The virtual Applied Genomics course blends foundational science, real-world case studies, and ethical discussions to prepare students for the future of precision medicine—before they even enter medical school.

JAX and the University of New England are preparing future health care providers for the era of precision medicine

11/04/2025

When her grandmother was diagnosed with Alzheimer’s disease, Kristen O’Connell saw firsthand how the illness reshapes identity, memory, and connection. Now, as a scientist at JAX, she’s leading research that brings us closer to preventing and treating this devastating condition.

10/31/2025

For nearly a century, JAX scientists have explored the genetic code to uncover the causes of disease and accelerate breakthroughs in medicine. From precision treatments to cutting-edge research models, JAX is turning bold ideas into real-world impact, improving outcomes for patients and families worldwide.

Join us as we reveal how JAX is shaping the future of medicine—one breakthrough at a time. Learn more at www.jax.org

10/30/2025

We sat down with Daniel Paull, JAX's new vice president of discovery and platform development, to talk about the JAX-NYSCF Collaborative, the importance of induced pluripotent stem cells, the future of precision medicine, and more.

Paull has spent his career at the intersection of biology and engineering. He oversees the NYSCF Global Stem Cell Array® and helped develop automation systems for generating iPSCs at unprecedented scale — advancing disease modeling and drug discovery. He leads NYSCF efforts to combine automation, imaging and AI to uncover hidden disease features.

Daniel Paull, who joins JAX from NYSCF as the vice president of discovery and platform development, has spent his career at the intersection of biology and engineering

10/28/2025

In his own words, JAX President and CEO Lon Cardon reflects on his vision for the JAX‑NYSCF Collaborative, and how this powerful partnership brings together people, ideas and innovation to accelerate discoveries and improve human health.

In his own words, JAX President and CEO Lon Cardon reflects on his vision for the JAX‑NYSCF Collaborative, and how this powerful partnership brings together people, ideas and innovation to accelerate discoveries and improve human health.

10/24/2025

🌍 300 million people worldwide live with a rare disease.
👶 Up to 75% are children.
💊 Only 5% of rare diseases have an FDA-approved therapy.

The JAX Rare Disease Translational Center is committed to changing these outcomes. Led by Vice President Cat Lutz, the team of 60+ scientists and staff are advancing rare disease research—bringing targeted therapies from the lab to the clinic faster.

➡️ Learn more about the RDTC below and here: https://www.jax.org/research-and-faculty/research-centers/rare-disease-translational-center/about

10/23/2025

Researchers and clinicians are both dedicated to improving human health, but researchers may not have the opportunity to fully understand how the intricate, complex work they conduct in the lab impacts a patient’s life.

A new course developed by JAX Genomic Education and the Maine Cancer Genomics Initiative, “Genomic Tumor Boards for Early Career Researchers,” is bridging the gap between research and patient care. A manuscript published recently in Nature Biotechnology emphasizes the key takeaways from the course including:

· Strengthen trainees’ ability to communicate scientific findings to clinicians
· Deepen their understanding of the clinical relevance of their work
· Introduce them to new career pathways
· Gain insight into the patient’s journey

Associate Director of MCGI, Leah Graham said, “Patient care can be so different than what students imagine it is. By giving them a window into that world, they discover just how unique and complex each and every patient truly is.”

Learn more: https://bit.ly/4qtcLDS

10/22/2025

The bold new alliance between The Jackson Laboratory (JAX) and The New York Stem Cell Foundation Research Institute promises to transform biomedical research and bring life-changing therapies to patients faster than ever before.

Learn more: www.jax.org/news-and-insights/2025/october/scope-speed-scale-

10/21/2025

“From the laboratory bench to the executive suite” — powerful insights on leadership, resilience, and purpose from Joanne Berger-Sweeney at this year’s Hewett Family Lecture held in Bar Harbor this month.

The lecture is part of the Hewett Leadership Program, JAX’s premier internal leadership development experience, made possible through the generosity of Chuck Hewett, former Executive Vice President and Chief Operating Officer for JAX, and his wife, Jackie Hewett. Designed to identify and elevate high-potential management and professional staff, this prestigious program offers immersive learning, hands-on experience with strategic projects, and executive engagement—recognizing and investing in the future leaders of JAX.

Congratulations to this year's Hewett Leadership participants, and thank you for continuing to inspire the future of nonprofit leadership in Maine and beyond.

10/20/2025

Introducing a new era of biomedical discovery.​
​
The Jackson Laboratory has acquired The New York Stem Cell Foundation Research Institute. This powerful new alliance brings together complementary strengths across mouse, cell, and computational systems — creating an unmatched platform to accelerate the pace of discovery and turn possibility into progress for patients around the world.

10/14/2025

✨ Hope for families facing rare brain tumors ✨

Intracranial germ cell tumors (IGCTs) are rare brain tumors that mostly affect teens and young adults. Getting the right diagnosis is critical—because each subtype needs different treatment—but traditional biopsies can be too risky.

That’s why our pediatric experts at Connecticut Children’s Research Institute, in partnership with The Jackson Laboratory, are leading a new global study using spinal fluid (a much safer test) to detect tumor-specific DNA changes. By studying 400 patients worldwide, we aim to give doctors faster, safer, and more accurate ways to diagnose and treat IGCTs—bringing hope to families everywhere. 💙